PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32100261-1	2020	BACKGROUND: As an important anti-HBV drug, pegylated interferon alpha (PegIFNalpha) offers promising clinical efficacy, but biomarkers that accurately forecast treatment responses are yet to be elucidated.	pegylated interferon alpha	43-69	interferon alpha 1	Homo sapiens	71-82	
32885325-2	2020	The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS.	pegylated interferon alpha	55-81	interferon alpha 1	Homo sapiens	83-91	
32885325-2	2020	The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS.	pegylated interferon alpha	55-81	interferon alpha 1	Homo sapiens	106-117	
34697111-1	2021	INTRODUCTION: Combination antiviral therapy of nucleos(t)ide analogue (NA) and pegylated interferon alpha (peg-IFN alpha) decrease hepatitis B virus (HBV) surface antigen (HBsAg) levels to achieve functional cure and improve long-term prognosis in chronic hepatitis B patients.	pegylated interferon alpha	79-105	interferon alpha 1	Homo sapiens	111-120